Fireside chat: BioSante's LibiGel and GVAX cancer vaccines portfolio

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that a BioSante presentation and corporate discussion are available at http://www.rodm.tv/video1269553400.

“This fireside chat is among the most far-reaching discussions we've ever had about our products and we are pleased to make it accessible. I would encourage all those interested in learning more about BioSante to visit the link, http://www.rodm.tv/video1269553400

Stephen M. Simes, president and CEO of BioSante presented an in-depth view of the Company's strategy, development pipeline and clinical milestones, during an interview by Elemer Piros, Ph.D., senior biotechnology analyst at Rodman & Renshaw, LLC (NASDAQ: RODM). The topics discussed included an overview of BioSante and specifically a thorough discussion of LibiGel® (testosterone gel), in development for the treatment of female sexual dysfunction, as well as BioSante's portfolio of GVAX cancer vaccines.

"This fireside chat is among the most far-reaching discussions we've ever had about our products and we are pleased to make it accessible. I would encourage all those interested in learning more about BioSante to visit the link, http://www.rodm.tv/video1269553400," said Simes.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough study unravels molecular subtypes of breast cancer